Foresee Pharmaceuticals Co Ltd Cash Flow Conversion Efficiency
Foresee Pharmaceuticals Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Foresee Pharmaceuticals Co Ltd (6576) has a cash flow conversion efficiency ratio of -0.162x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-157.53 Million ≈ $-4.96 Million USD) by net assets (NT$971.84 Million ≈ $30.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Foresee Pharmaceuticals Co Ltd (2017–2024)
Cash flow conversion efficiency of Foresee Pharmaceuticals Co Ltd from 2017 to 2024. This chart illustrates how Foresee Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 6576 stock price and chart for real-time trading data and today's change.
Foresee Pharmaceuticals Co Ltd Cash Flow Conversion Ratio Explained
Foresee Pharmaceuticals Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Foresee Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Foresee Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency. Also see market cap of Foresee Pharmaceuticals Co Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ophir High Conviction Fund
AU:OPH
|
-0.029x |
|
Jiangsu Yida Chemical Co Ltd Class A
SHE:300721
|
-0.095x |
|
Jinsanjiang (Zhaoqing) Silicon Material Company Limited
SHE:301059
|
N/A |
|
Shanxi Yongdong Chemistry Industry Co Ltd
SHE:002753
|
0.000x |
|
Equinox India Developments Ltd
NSE:IBREALEST
|
0.001x |
|
Agro Tech Foods Limited
NSE:ATFL
|
0.022x |
|
Aurora Corp
TW:2373
|
-0.013x |
|
Tus-Sound Environmental Resources Co Ltd
SHE:000826
|
-0.402x |
Annual Cash Flow Conversion Efficiency for Foresee Pharmaceuticals Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Foresee Pharmaceuticals Co Ltd from 2017 to 2024. Review 6576 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.60 Billion ≈ $50.38 Million |
NT$-1.17 Billion ≈ $-36.98 Million |
-0.734x | -2.93% |
| 2023-12-31 | NT$1.24 Billion ≈ $39.21 Million |
NT$-887.55 Million ≈ $-27.96 Million |
-0.713x | -178.45% |
| 2022-12-31 | NT$910.58 Million ≈ $28.69 Million |
NT$-233.22 Million ≈ $-7.35 Million |
-0.256x | -58.50% |
| 2021-12-31 | NT$1.32 Billion ≈ $41.59 Million |
NT$-213.33 Million ≈ $-6.72 Million |
-0.162x | +56.19% |
| 2020-12-31 | NT$1.83 Billion ≈ $57.63 Million |
NT$-674.80 Million ≈ $-21.26 Million |
-0.369x | +26.20% |
| 2019-12-31 | NT$895.86 Million ≈ $28.22 Million |
NT$-447.82 Million ≈ $-14.11 Million |
-0.500x | +46.10% |
| 2018-12-31 | NT$498.62 Million ≈ $15.71 Million |
NT$-462.43 Million ≈ $-14.57 Million |
-0.927x | -15.89% |
| 2017-12-31 | NT$603.66 Million ≈ $19.02 Million |
NT$-483.10 Million ≈ $-15.22 Million |
-0.800x | -- |
About Foresee Pharmaceuticals Co Ltd
Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release … Read more